In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy ...

The new multi-month subscription program launched March 31, 2026 offers eligible self-pay patients a fixed monthly price for ...

Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $47 per share, valuing the deal at approximately $7.8 billion.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

Approval of Biogen's high-dose Spinraza strengthens the company’s lifecycle strategy in SMA, enhancing durability while reinforcing competitive positioning in a rapidly evolving neurology market.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by ...

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

Chris Dowd and Lisa Prowker of ConnectiveRx discuss point-of-care marketing as the key activation layer for investments in ...

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework ...

The agreement grants Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics. Do you know someone who can make tough decisions that continue to face manufacturers? Are ...

Eli Lilly warns that the UK's current framework is undermining investment and could impact future launches and manufacturing decisions. Do you know someone who can make tough decisions that continue ...

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach his company took to developing its core technology. According to him, the ...